Equity Research · Wednesday, September 9, 2026
ATR Stock Analysis for September 2026
AptarGroup, Inc.
Price at Analysis
1Y Price Target
$130.00
+4.6%
vs current price
Technical Setup
RSI 28 / bearish MACD
Support context: $103.23. Resistance context: $146.91.
Valuation Snapshot
P/E ~22-23x forward (est. ~$5.50 annualized adjusted EPS) / P/S ~2.0x (est. ~$4.0B annual revenue)
Market cap $8.10B; revenue $1.03B Q2 2026 (first $1B+ quarter, +6% reported).
Risk Watch
Stalled core/organic growth
Core sales were flat in Q1 and +1% in Q2 — reported growth is largely FX and acquisition driven. Without organic reacceleration, multiple expansion is unlikely.
01 · Summary
Executive Summary
AptarGroup is a high-quality, niche-dominant franchise in drug delivery and dispensing systems, with Pharma generating over two-thirds of group profits. The stock trades at $124.34, down 15.4% from its 52-week high, with an RSI of 27.9 indicating oversold conditions. Fundamentals are mixed but not broken: Q2 2026 marked the first $1B+ revenue quarter ($1.03B, +6% reported) with adjusted EPS of $1.42 beating estimates by ~4%, but core sales growth was just 1% and Q1 showed margin compression (adjusted EBITDA margin of 19.2% vs 20.7%). The bear case is real: organic growth has stalled, currency and acquisitions are doing the heavy lifting on reported growth, and a CEO transition introduces execution uncertainty. The bull case rests on secular pharma packaging tailwinds (injectables, ophthalmic, sustainability-driven demand), margin recovery potential, and a valuation (~$8.1B market cap, roughly 22-23x forward earnings) that is reasonable — not cheap — for a business of this quality. My verdict is neutral. This is a fine company at a fair price facing a genuine organic growth deceleration that the market has already partially priced in. The oversold technicals limit near-term downside, but without core growth reacceleration there is no catalyst for meaningful multiple expansion. I expect the stock to grind higher modestly as margins stabilize, but not deliver outsized returns over 1-3 years.
02 · Scenario Modeling
Price Targets
$130.00+4.6%
$142.00+14.2%
1-Year scenario price targets · Dashed line = current price
02 · Scenario Modeling
Scenario Analysis
| Scenario | 1Y Target | 1Y Growth | 3Y Target | 3Y Growth |
|---|---|---|---|---|
↑↑Hyper Bull | $175.00 | +40.7% | $215.00 | +72.9% |
↑Bull | $142.00 | +14.2% | $165.00 | +32.7% |
→Neutral | $130.00 | +4.6% | $142.00 | +14.2% |
↓Bear | $108.00 | -13.1% | $100.00 | -19.6% |
↓↓Hyper Bear | $90.00 | -27.6% | $80.00 | -35.7% |
03 · Fundamentals
Key Financial Metrics
- Earnings Per Share (EPS)
- $1.42 Q2 2026 adjusted; $1.19 Q1 2026 adjusted
- Revenue
- $1.03B Q2 2026 (first $1B+ quarter, +6% reported)
- P/E Ratio
- ~22-23x forward (est. ~$5.50 annualized adjusted EPS)
- P/S Ratio
- ~2.0x (est. ~$4.0B annual revenue)
- Market Cap
- $8.10B
- Net Income
- N/A (Q2 adjusted EPS $1.42)
- Dividend Yield
- ~2% (est.)
- Short Interest
- N/A (no ATR-specific data; no elevated short thesis evident)
- 52-Week Low
- $103.23
- 52-Week High
- $146.91
02 · Scenario Modeling
Technical Overview
Quant overlays derived from the existing 1Y OHLCV series: trend stack, sigma bands, regression fit, drawdown regime, and a composite signal model.
RSI (14)
27.9
Momentum Stack
1M -8.2% / 3M +11.1%
Volatility Regime
14.3% 20D vol
Regression Fit
-2.1% vs trend
Drawdown Curve
Distance from rolling peak, useful for regime stress and recovery speed.
-14.7%
Trend Regime
neutral
Mixed stack
Composite Signal
neutral
Neutral (+0)
Mean Reversion
bearish
-2.86 sigma
Breakout Status
bearish
Below 20D low
Range Percentile
neutral
48th pct
Volume Impulse
neutral
0.98x 20D avg
Quant Dashboard
A compact read on trend persistence, stretch, realized risk, and breakout behavior.
- 1M Return
- -8.2%
- 6M Return
- -7.0%
- 1Y Return
- N/A
- ATR (14)
- $2.40
- 20D Vol
- 14.3%
- 60D Vol
- 21.7%
- Regression R²
- 0.00
- Price Z-Score
- -2.86
- 52W High
- $146.91
- 52W Low
- $103.23
- Range Position
- 48th pct
- Latest Volume
- 362.2K
04 · Research
Micro Analysis
AptarGroup's Q2 2026 results showed record quarterly revenue above $1B with 6% reported growth, but core sales grew only 1%, revealing reliance on FX and the Sommaplast acquisition. Q1 exposed margin pressure (EBITDA margin down 150bps YoY to 19.2%) from unfavorable product mix, while Q2 EBITDA margins recovered to 22.6%. The Pharma segment (2/3+ of profits) remains the key growth engine, supported by active-to-market drug delivery programs and the Sommaplast acquisition expanding the pharma portfolio. A smooth internal CEO transition (Gael Touya, former Pharma president) supports strategic continuity.
Organic growth deceleration
Q1 core sales flat, Q2 core sales up just 1% — reported growth of 6-11% is heavily FX- and M&A-driven. This is the central fundamental problem the market is repricing.
Margin volatility
Q1 adjusted EBITDA margin fell to 19.2% from 20.7% on product mix; Q2 recovered to 22.6% with EPS of $1.42 beating consensus by 3.8%. Margin stability, not expansion, is the base case.
Pharma segment quality
Pharma generates over two-thirds of group profits with high switching costs and long product lifecycles; the December 2025 Sommaplast acquisition and Ophthalmic Squeeze Dispenser momentum reinforce competitive moats.
Leadership transition
Internal promotion of Gael Touya (Pharma president) to CEO signals continuity, but transitions add near-term uncertainty and the stock fell ~4% on the announcement.
Technically oversold
RSI of 27.9 with the stock 15.4% below its 52-week high and 20.5% above its low — downside appears partially exhausted absent a fundamental deterioration.
04 · Research
Macro Analysis
Aptar's end markets are structurally supported: pharmaceutical packaging is projected to exceed $219B by 2031, cosmetic packaging to reach $61.5B by 2032 (5.76% CAGR), and pharmaceutical glass packaging to nearly double to $12.4B by 2035. With 49% of sales from Europe and 28% from the U.S., currency swings are a material reported-results driver — currently a tailwind. Consumer health demand normalization and persistent resin/pricing pressures in plastics are headwinds, but sustainability and injectable drug trends favor Aptar's premium dispensing technologies.
Secular pharma packaging growth
Injectable drug packaging, smart packaging/RFID, and ophthalmic delivery are all forecast to grow above GDP through 2031-2035, directly benefiting Aptar's highest-margin segment.
Currency tailwind
With ~49% of sales in Europe, the weaker dollar has inflated reported sales (Q1 +11% reported vs flat core) — a benefit that could reverse if FX shifts.
Consumer demand normalization
Beauty and Closures face sluggish developed-market consumer demand; flat core sales reflect a normalizing post-COVID environment rather than share loss.
Sustainability regulation
EU packaging and sustainability rules favor Aptar's recyclable and refillable dispensing innovations, creating both cost pressure and competitive differentiation.
05 · Growth
Untapped Revenue Opportunities
Injectable drug delivery systems
highRising demand for injectable biologics drives growth in Aptar's pharma delivery devices and specialized closures; pharma glass packaging market expected to double to $12.4B by 2035.
Sommaplast integration and pharma portfolio expansion
mediumDecember 2025 acquisition broadens Aptar's pharmaceutical packaging portfolio and cross-selling reach in fast-growing segments.
Premium and sustainable cosmetic dispensing
mediumCosmetic packaging market growing at 5.76% CAGR to $61.5B by 2032; Aptar's high-performance, refillable dispensing systems are positioned in the fastest-growing premium/sustainable niches.
Smart packaging and RFID-enabled pharma verification
mediumSmart packaging innovation (RFID-enabled verification) in a pharma packaging market exceeding $219B by 2031 offers a differentiated growth vector.
06 · Catalysts
Headwinds & Tailwinds
↓ Headwinds
Stalled core/organic growth
highCore sales were flat in Q1 and +1% in Q2 — reported growth is largely FX and acquisition driven. Without organic reacceleration, multiple expansion is unlikely.
Product mix margin pressure
mediumQ1 adjusted EBITDA margin fell 150bps YoY to 19.2%; mix headwinds could persist if lower-margin Beauty/Closures growth outpaces Pharma.
FX reversal risk
mediumWith nearly half of sales in Europe, a dollar-strengthening scenario would erase the reported growth benefit and pressure translated earnings.
CEO transition execution risk
lowLeadership handoff to Gael Touya, while internally sourced, creates uncertainty on capital allocation and strategy continuity; the stock fell ~4% on the news.
Consumer end-market softness
mediumDeveloped-market consumer demand normalization keeps Beauty and Closures volumes sluggish, limiting upside from those segments.
↑ Tailwinds
Pharma packaging secular growth
highPharma packaging market projected to exceed $219B by 2031, with injectables and specialized closures growing fastest — Aptar's profit engine sits in the sweet spot.
Record quarterly revenue and EPS beats
mediumFirst-ever $1B+ quarter ($1.03B, +6%) and Q2 adjusted EPS of $1.42 beating estimates by 3.8% with 22.6% EBITDA margins demonstrate operational resilience.
Oversold technical setup
mediumRSI at 27.9 and the stock 15.4% off its high suggest negative sentiment is largely priced in, limiting near-term downside.
Sustainability-driven demand
mediumEU sustainability regulations and premium/sustainable packaging trends favor Aptar's innovative, recyclable dispensing technologies over commodity competitors.
07 · TL;DR
Analysis Summary
- Ticker
- ATR
- Company
- AptarGroup, Inc.
- Analysis Date
- 2026-09-09
- Price at Analysis
- $124.34
- Rating
- Hold
- 1Y Price Target
- $130.00
- 3Y Price Target
- $142.00
- Market Cap
- $8.10B
- P/E Ratio
- ~22-23x forward (est. ~$5.50 annualized adjusted EPS)
This analysis was generated on 2026-09-09 when ATR was trading at $124.34. The base-case 1-year price target is $130.00 (+4.6% implied return). Scenario range: $90.00 (hyper bear) to $175.00 (hyper bull).